The forecast for the total number of 10% top-cited scientific publications in drug discovery in Japan indicates a consistent decline from 2024 to 2028, starting at 12.6 publications in 2024 and descending to 11.62 by 2028. Compared to the actual data from 2023, this represents a negative trend where the compound annual growth rate (CAGR) shows an average decrease over the five years.
Future trends to watch for include advancements in AI-driven drug discovery and international collaborations, which could influence the number and influence of publications. Additionally, Japan's focus on personalized medicine and investment in R&D may alter this trajectory and mitigate declines.
